Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): Study protocol

BMJ Open

Volumn 3, Issue 7, 2013, Pages

  Horne, Andrew W ^a   Skubisz, Monika M ^b   Doust, Ann ^a   Duncan, W Colin ^a   Wallace, Euan ^c   Critchley, Hilary O D ^a   Johns, Terrance G ^c   Norman, Jane E ^a   Bhattacharya, Siladitya ^d   Mollison, Jill ^d   Rassmusen, Michael ^e   Tong, Stephen ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; GEFITINIB; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECTOPIC PREGNANCY; FEMALE; HUMAN; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; SINGLE DRUG DOSE; TUBAL ECTOPIC PREGNANCY;

EID: 84880630861     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002902     Document Type: Article

References (15)

1. Sivalingam VN, Duncan WC, Kirk E, et al. Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health Care 2011;37:231-40.
2. Jurkovic D, Wilkinson H. Diagnosis and management of ectopic pregnancy. BMJ 2011;342:d3397.
3. RCOG. The management of tubal pregnancy. Green top Guideline No 21, published in May 2004 (reviewed 2010). http://www.rcog.org. uk/files/rcog-corp/ GTG21-230611.pdf
4. Mavrelos D, Nicks H, Jamil A, et al. Efficacy and safety of a clinical protocol for expectant management of selected women diagnosed with a tubal ectopic pregnancy. Ultrasound Obstet Gynecol 2013;42:102-7.
5. Van Mello NM, Mol F, Verhoeve HR, et al. Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations? A randomized comparison. Hum Reprod 2013;28:60-7.
6. Mol F, Mol BW, Ankum WM, et al. Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 2008;14:309-19. (Pubitemid 351858971)
7. Herbst RS, Fukvoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65. (Pubitemid 39626219)
8. Nilsson UW, Johns TG, Wilmann T, et al. Effects of Gefinitb, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth. Obstet Gynecol. In press.
9. Skubisz MM, Horne AW, Johns TG, et al. Combination Gefitinib and Methotrexate Compared with Methotrexate Alone to Treat Ectopic Pregnancy. Obstet Gynecol. In press.
10. A'Hern RP. Sample size tables for exact single stage Phase II designs. Stat Med 2001;20:859-866. (Pubitemid 32249085)
11. Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007;87:481-4. (Pubitemid 46385986)
12. Barnhart K, Van Mello NM, Bourne T, et al. Pregnancy of unknown location: a consensus statement of nomenclature, definitions, and outcome. Fertil Steril 2011;95:857-66.
13. Fauconnier A, Mabrouk A, Salomon LJ, et al. Ultrasound assessment of haemoperitoneum in ectopic pregnancy: derivation of a prediction model. World J Emerg Surg 2007;2:23.
14. Menon S, Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007;87:481-4. (Pubitemid 46385986)
15. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-18. (Pubitemid 38365209)